MOODY’S-ANALYTICS
Moody’s Analytics, a leading provider of financial intelligence, has announced that Greek digital bank, Praxia bank , has selected the Moody’s Analytics suite of regulatory solutions for asset liability management (ALM), IFRS 9, and Basel III compliance.
Praxia bank will use the Moody’s Analytics RiskFoundation™ platform to consolidate and centralize risk management data across its organization using one solution. The award-winning platform delivers a standardized single point of control for performing risk analysis and regulatory reporting tasks, enabling the bank to best utilize its IT investment and execute a consistent enterprise-wide risk management strategy.
Praxia bank will also use the award-winning Moody’s Analytics RiskConfidence™ solution for IFRS 9, and ALM and liquidity risk management. The integrated solution will allow the bank to efficiently cover ALM and liquidity risk.
For Basel III compliance , Praxia bank has selected the RiskAuthority™ software, a comprehensive solution covering data management, regulatory capital calculations, and supervising reporting requirements. Its embedded Basel III calculation ratios and automated workflow processes will enable the bank to deliver efficient and streamlined Basel III compliance while leveraging the automation the solution affords.
“Working with one technology vendor brings significant advantages from an implementation and operations perspective,” said Thanos Papanikolaou, Chief Risk Officer at Praxia bank. “In view of our launch in Greece, we have proudly selected Moody’s Analytics to be our strategic partner. Its platforms allow us to efficiently monitor and manage risk, as well as support the various – and evolving - compliance and regulatory guidelines.”
“As banks globally look for ways to extract value from their regulatory technology investment, there is increasing demand for solutions that enable financial institutions to create synergies between compliance and business optimization,” said Andy Frepp, General Manager at Moody’s Analytics. “We look forward to working with Praxia bank to provide regulatory technology that supports their vision while offering a leaner, more agile approach to risk management.”
Click here to learn more about the Moody’s Analytics suite of regulatory reporting solutions.
About Moody’s Analytics
Moody’s Analytics provides financial
intelligence and analytical tools to help business leaders make better,
faster decisions. Our deep risk expertise, expansive information
resources, and innovative application of technology help our clients
confidently navigate an evolving marketplace. We are known for our
industry-leading and award-winning solutions, made up of research, data,
software, and professional services, assembled to deliver a seamless
customer experience. We create confidence in thousands of organizations
worldwide, with our commitment to excellence, open mindset approach, and
focus on meeting customer needs. For more information about Moody’s
Analytics, visit our website
or connect with us on Twitter
or LinkedIn
.
Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.
About Praxia bank
Praxia bank was created in 2018 and is
expected to fully launch within 2019. Praxia bank is a privately-owned
bank with a solid international shareholder structure operating under
the supervision of the Bank of Greece. Deposits are protected by the
Hellenic Deposit & Investment Guarantee Fund. Praxia bank’s executive
team includes talented professionals who bring a wealth of local and
international banking experience and share a common vision: to offer a
sophisticated banking experience that is more humane and at the same
time more digital than ever, to meet the needs of small and medium-sized
businesses as well as retail customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005323/en/
Contact:
TRACEY SCOTT Moody’s Analytics Communications +44.207.772.5207 Moody’s Analytics Media Relations
moodysanalytics.com twitter.com/moodysanalytics linkedin.com/company/moodysanalytics
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom